Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Louis Velazquez

Main PageFebruary 12, 2025

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent